The pharmaceutical subsidiary plans to capture a large portion of the growing market with innovative formulation methods.
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) — Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada”, the “Company”) today announced that Genefic, Inc., its wholly owned healthcare subsidiary, ”) was announced. is adding telemedicine services to its specialty pharmacies, giving customers direct access to its medicines, including access to Genefic's proprietary weight loss medicines, as its subsidiary enters the fast-growing global weight loss drug market. can now be provided efficiently.
The global weight loss drug market size is currently around $6 billion and is expected to reach nearly $100 billion by the end of 2020, with the market value rapidly increasing due to the popularity of weight loss drugs overall.
Additionally, the company's expected compound annual growth rate (CAGR) of 45.7% suggests that 2024 is the ideal time for Genefic to enter the weight loss drug market, according to Dan Riley, president of the subsidiary.
“With the use of our powerful new telemedicine services, we are now able to offer a selection of the most successful weight loss medications on the market today,” said Riley. He added: “Genefic already partners with one of the world's leading weight loss providers, which has been accepted in the market for over 20 years. We are excited that this will accelerate the further expansion of our customer base. recognizing.”
With the growing awareness and awareness of the effectiveness of weight loss drugs, celebrities such as Oprah Winfrey, Elon Musk, Tracy Morgan, and Kelly Clarkson are touting their success, and the general public is following suit.
Brian Bonner, CEO of Dalrada, added: Tapping into the weight loss drug market will give you a wider reach than ever before and will generate significant revenue. ”
About Dalrada Corporation
Dalrada Financial Corporation (OTCQB: DFCO) is a multinational holding company that develops, manufactures and markets powerful products and services in the clean energy and healthcare sectors. Dalrada's core divisions include Dalrada Climate Technology, which provides cutting-edge heat pump technology for industrial and residential applications, and Genefique Specialty Pharmacy, which provides end-to-end prescription services and patient advocacy and support. It is included.
Dalrada Financial Corporation consistently drives innovation for maximum impact, creating greater value for our shareholders.
For more information, please visit www.dalrada.com or follow us on LinkedIn, Facebook, Twitter and YouTube.
About Genefic
Genefic, a wholly owned subsidiary of Dalrada Financial Corporation, proudly delivers cutting-edge health products and services through redesigned systems and reimagined patient care. Genefic's unique pharmacy solution, Genefic Specialty Pharmacy, brings over 30 years of expertise and provides patient advocacy through end-to-end prescription services, medical education, patient advocacy and support.
Forward-looking statements
Statements contained in this press release, other than statements of historical fact, include, among other things, statements regarding cost reductions and anticipated pre-tax savings from cost reduction programs, cost restructuring, footprint rationalization and streamlining of our operations. and statements about streamlining, reducing complexity, and strengthening systems. The speed with which we make decisions utilizing our procurement capabilities and the timing of implementation and completion of cost reduction programs are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the following beliefs: and management's assumptions based on information available to the Company at the time such statements are made. These statements generally include words such as “will,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “anticipate,” “plan,” and “project.” ”, and similar expressions are made as of the date hereof and involve certain risks and uncertainties, and we undertake no obligation to update them. Forward-looking statements are subject to the occurrence of many events and actual results beyond our control, and the timing of events is subject to a number of factors that involve substantial known and unknown risks. may differ materially from those suggested or implied by such forward-looking statements. Uncertainty. Factors that may affect our success are disclosed in more detail in our most recent public filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K. Masu.
Media Contact: Isabella Monteparte (imonteparte@genefic.com)
